Compositions from gastrointestinal tract mucins, and uses thereof
AssigneeGnubiotics Sciences SA
InventorsSara Vidal López, Adeyemi Adesokan, Yong Miao
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions comprising glycopeptides obtained from gastrointestinal mucins that have superior microbiota affects, and methods of manufacture and use thereof. Such compositions are advantageous for pharmaceutical, food stuff and pet food applications.
Claims20
A method of treating, preventing, or reducing the severity of a pathogenic microorganism infection of the gut of a subject comprising orally administering to the subject a composition comprising a mixture of glycopeptides obtained from gastrointestinal tract mucins or a partially purified fraction thereof, wherein:
- a) the composition is obtained without subjecting the mucins or the partially purified fraction thereof to conditions or reagents that release oligosaccharides from glycopeptides;
- b) the oligosaccharide content of the composition is >2% (w/w);
- c) the peptide content of the composition, for peptides with a molecular weight of 5 KDa or less, is >40% (w/w);
- d) the free amino acid content of the composition is <45% (w/w);
- e) the water solubility of the mixture of glycopeptides is greater than 120 g/L at 25° C.;
- f) the composition comprises glycopeptide-bound oligosaccharides having each of the following general formulae:
- i. Hex1HexNAc1
- ii. HexNAc2
- iii. NeuAc1HexNAc1
- iv. NeuGc1HexNAc1
- v. Hex1HexNAc1Fuc1
- vi. Hex1HexNAc2
- vii. Hex1HexNAc2Sul1
- viii. NeuAc1Hex1HexNAc1
- ix. NeuGc1Hex1HexNAc1
- x. NeuAc1HexNAc2
- xi. NeuGc1HexNAc2
- xii. Hex1HexNAc2Fuc1
- xiii. Hex1HexNAc2Fuc1Sul1
- xiv. NeuAc1Hex1HexNAc1Fuc1
- xv. Hex1HexNAc3Sul1
- xvi. Hex2HexNAc2Fuc1
- xvii. Hex1HexNAc3Fuc1Sul1
- xviii. Hex2HexNAc2Fuc2Sul1, and
- g) the composition has been filtered to remove insoluble particles having a diameter greater than 7 μm.
A method of increasing the growth of commensal bacteria in the gut of a subject comprising orally administering to the subject a composition comprising a mixture of glycopeptides obtained from gastrointestinal tract mucins or a partially purified fraction thereof, wherein:
- a) the composition is obtained without subjecting the mucins or the partially purified fraction thereof to conditions or reagents that release oligosaccharides from glycopeptides;
- b) the oligosaccharide content of the composition is >2% (w/w);
- c) the peptide content of the composition, for peptides with a molecular weight of 5 KDa or less, is >40% (w/w);
- d) the free amino acid content of the composition is <45% (w/w);
- e) the water solubility of the mixture of glycopeptides is greater than 120 g/L at 25° C.;
- f) the composition comprises glycopeptide-bound oligosaccharides having each of the following general formulae:
- i. Hex1HexNAc1
- ii. HexNAc2
- iii. NeuAc1HexNAc1
- iv. NeuGc1HexNAc1
- v. Hex1HexNAc1Fuc1
- vi. Hex1HexNAc2
- vii. Hex1HexNAc2Sul1
- viii. NeuAc1Hex1HexNAc1
- ix. NeuGc1Hex1HexNAc1
- x. NeuAc1HexNAc2
- xi. NeuGc1HexNAc2
- xii. Hex1HexNAc2Fuc1
- xiii. Hex1HexNAc2Fuc1Sul1
- xiv. NeuAc1Hex1HexNAc1Fuc1
- xv. Hex1HexNAc3Sul1
- xvi. Hex2HexNAc2Fuc1
- xvii. Hex1HexNAc3Fuc1Sul1
- xviii. Hex2HexNAc2Fuc2Sul1, and
- g) the composition has been filtered to remove insoluble particles having a diameter greater than 7 μm.
A method of increasing production of short chain fatty acid (SCFA) in the gut of a subject comprising orally administering to the subject a composition comprising a mixture of glycopeptides obtained from gastrointestinal tract mucins or a partially purified fraction thereof, wherein:
- a) the composition is obtained without subjecting the mucins or the partially purified fraction thereof to conditions or reagents that release oligosaccharides from glycopeptides;
- b) the oligosaccharide content of the composition is >2% (w/w);
- c) the peptide content of the composition, for peptides with a molecular weight of 5 KDa or less, is >40% (w/w);
- d) the free amino acid content of the composition is <45% (w/w);
- e) the water solubility of the mixture of glycopeptides is greater than 120 g/L at 25° C.;
- f) the composition comprises glycopeptide-bound oligosaccharides having each of the following general formulae:
- i. Hex1HexNAc1
- ii. HexNAC2
- iii. NeuAc1HexNAc1
- iv. NeuGc1HexNAc1
- v. Hex1HexNAc1Fuc1
- vi. Hex1HexNAc2
- vii. Hex1HexNAc2Sul1
- viii. NeuAc1Hex1HexNAc1
- ix. NeuGc1Hex1HexNAc1
- x. NeuAc1HexNAc2
- xi. NeuGc1HexNAc2
- xii. Hex1HexNAc2Fuc1
- xiii. Hex1HexNAc2Fuc1Sul1
- xiv. NeuAc1Hex1HexNAc1Fuc1
- xv. Hex1HexNAc3Sul1
- xvi. Hex2HexNAc2Fuc1
- xvii. Hex1HexNAc3Fuc1Sul1
- xviii. Hex2HexNAc2Fuc2Sul1, and
- g) the composition has been filtered to remove insoluble particles having a diameter greater than 7 μm.
Dependencies are inferred from the claim text.